Companies Dominating the Cancer Cachexia Market
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Veru Inc.
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Mylan N.V.
- ANI Pharmaceuticals
- Novartis AG
- Hikma Pharmaceuticals Plc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Cancer Cachexia Market in 2025 is assessed at USD 2.59 billion.
The global market size was worth over USD 2.49 billion in 2024 and is poised to grow at a CAGR of around 5%, reaching USD 4.7 billion revenue by 2037.
North America is likely to attain USD 1.41 billion by 2037, fueled by rising prevalence of chronic illnesses like cancer and expanding knowledge of cachexia treatments.
The major players in the market include Veru, Inc, Eli Lilly and company, Bristol-Myers Squibb Company, Mylan N.V., ANI Pharmaceuticals, Novartis AG, Hikma Pharmaceuticals Plc., Sun pharmaceutical Industries Ltd.
